Immunogenicity and Safety in Adults

摘要: During the past decade, a number of studies have evaluated immunogenicity and safety various pneumococcal conjugate vaccine (PCV) formulations in immunocompromised immunocompetent adults. This chapter summarizes findings from evaluations PCVs Two early immune response to monovalent PCV by using radioimmunoassays, but since that time, all clinical adults assessed immunoglobulin G (IgG) antibody enzyme-linked immunosorbent assays (ELISAs) and, some cases, additional immunologic assays, such as opsonophagocytic assay (OPA). were conducted among different populations used laboratories for ELISA, which been standardized give similar results laboratories. The geometric mean concentrations (GMCs) are strikingly similar, suggesting administration polysaccharide (PPSV) may induce hyporesponsiveness persists at least 5 years. defines booster simply one involving significantly higher levels PCV-primed individuals than unprimed following standard licensed dose PPSV. well tolerated experience with described published reports is limited, conclusions about must be viewed preliminary subject confirmation larger, controlled studies.